Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia

MLA

Kathryn Humphrey, et al. Phase 1b Study of Venetoclax-Obinutuzumab in Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia. June 2019. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....5c6a42d530e3e256cd7d06e6bf8944ef&authtype=sso&custid=ns315887.

APA

Kathryn Humphrey, Maria Verdugo, Peter Hillmen, Thomas J. Kipps, Ian W. Flinn, Kerry A. Rogers, Mehrdad Mobasher, John G. Gribben, Loic Ysebaert, Gerard Lozanski, Daniela Soriano Pignataro, Richard R. Furman, Martin J. S. Dyer, Swaminathan P. Iyer, Anne Quillet-Mary, Yanwen Jiang, William G. Wierda, Huang Huang, Michael B. Maris, … Christian Klein. (2019). Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia.

Chicago

Kathryn Humphrey, Maria Verdugo, Peter Hillmen, Thomas J. Kipps, Ian W. Flinn, Kerry A. Rogers, Mehrdad Mobasher, et al. 2019. “Phase 1b Study of Venetoclax-Obinutuzumab in Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia,” June. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....5c6a42d530e3e256cd7d06e6bf8944ef&authtype=sso&custid=ns315887.